RecruitingMild Alzheimer's DiseaseMild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Eligible age
All ages
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
Sponsor: Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
You may qualify if…
- ✓ Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.
You may not qualify if…
- ✕ none
Where it's recruiting
Maryland
Baltimore
Source: ClinicalTrials.gov · NCT06058234 · last updated 2023-09-28